|
|
|
| Efficacy of Peg-IFNα-2a Combined with ADV on Hepatitis B Virus E Antigen-Positive Chronic Hepatitis B with High Viral Load |
| ZHOU Juan, ZHANG Wenfang |
| Wuhan Fifth Hospital, Hubei Wuhan 430050, China |
|
|
|
|
Abstract Objective: To explore the efficacy of Peg-interferon α-2a (Peg-IFNα-2a) combined with adefovir dipivoxil (ADV) on HbeAg-positive chronic hepatitis B patients with high viral load. Methods: 132 cases of HbeAg-positive chronic hepatitis B patients with high viral load were randomly divided into interferon group, ADV group and combined group, with 44 cases in each group. Interferon group was administered Peg-IFNα-2a, and ADV group was administered ADV, and combined group was firstly treated with ADV to control the reduction of viral load, and then Peg-IFNα-2a was administered additionally. Hepatitis B virus marker conversion, serological marker conversion, virological and serological response after 48 w of treatment, levels of serum interferon-γ (INF-γ) and interleukin-10 (IL-10) before treatment and after 48 w of treatment were observed among the three groups. Results: The alanine aminotransferase (ALT) reversion rate, HBV-DNA negative conversion rate and HBsAg negative conversion rate in combined group were significantly higher than those in interferon group and ADV group (P<0.0167), and the HBeAg seroconversion rate was significantly higher than that in ADV group (P<0.0167), and the differences among the three groups were statistically significant (P<0.0167). The complete virological response rate in combined group was significantly higher than that in interferon group and ADV group (P<0.0167) while the non-response rate was significantly lower than that in interferon group and ADV group (P<0.0167), and there were statistically significant differences among the three groups in the improvement of virological and serological response (P<0.05). After treatment, the INF-γ level in the three groups was significantly increased (P<0.05) while the IL-10 level was significantly decreased (P<0.05), and the changes in combined group were significantly greater than those in interferon group and ADV group (P<0.05). There were no statistically significant differences in the incidence rates of influenza-like symptoms, insomnia, alopecia, neutropenia and platelet count reduction between combined group and interferon group (P>0.0167), and the incidence rates were significantly higher than those in ADV group (P<0.0167). Conclusion: Peg-IFNα-2a combined with ADV for HbeAg-positive chronic hepatitis B patients with high viral load can improve ALT reversion rate, HBV-DNA negative conversion rate, HBsAg negative conversion rate and HBeAg seroconversion rate, and it is conducive to inhibiting viral replication capacity and virological and serological response rates, thus it can be safely promoted in the clinical practice.
|
|
|
|
|
|
[1] 张蕾.扶正化瘀胶囊联合恩替卡韦和熊去氧胆酸对HBeAg阳性高病毒载量乙肝肝硬化患者抗病毒疗效及肝功能、肝纤维化和炎症反应的影响[J].药物评价研究,2019,42(4):739~742.
[2] 朱芳,周付成,费媛媛,等.聚乙二醇干扰素α-2a或α-2b联合利巴韦林治疗慢性丙型肝炎的疗效及安全性[J].江苏医药,2018,44(1):47~50.
[3] 石莹莹,王元喜.替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响[J].实用肝脏病杂志2019,22(6):820~823.
[4] 慢性乙型肝炎抗病毒治疗专家共识专家委员会.慢性乙型肝炎抗病毒治疗专家共识[J].中华实验和临床染病杂志(电子版),2010,2(1):125~130.
[5] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[M].第一次全国中西医结合传染病学术会议论文汇编,2006.62~68.
[6] 吕建林,毛德文,张荣臻,等.柴芍六君子汤联合PegIFNα-2a治疗HBeAg阳性慢性乙型肝炎的临床观察[J].中国中西医结合消化杂志,2018,26(2):145~151.
[7] 高晓红,郝晓芳,景鹏.不同核苷(酸)类药物长期治疗对乙型肝炎肝硬化的影响[J].肝脏,2020,25(4):396~400.
[8] 高媛娇,李明慧,谢尧,等.HBeAg阴性慢性乙型肝炎核苷(酸)类似物序贯干扰素治疗疗效的相关因素研究[J].中华实验和临床病毒学杂志,2018,32(5):533~537.
[9] 陈若雷.替诺福韦酯联合拉米夫定抗病毒治疗对耐药慢性乙肝患者HBVDNA转阴率及HBeAg阳性血清学转换率的影响[J].中国医师杂志,2018,20(10):1576~1579.
[10] 汪波,刘艳艳,李家斌.Peg-IFNα-2b单药或联合阿德福韦对前C区BCP区突变慢性乙型肝炎患者疗效比较研究[J].安徽医科大学学报,2018,53(10)1606~1609.
[11] 武晓丽.PEG-IFNα-2a与阿德福韦酯的联用方式对HBeAg阳性慢性乙型肝炎疗效的影响[J]临床肝胆病杂志.2017,33(12):2311~2315. |
|
|
|
2021, Vol. 27 
